{"id":"clarithromycin-rifabutin","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)"},{"rate":"5-15","effect":"Taste disturbance"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Uveitis (rifabutin-associated)"},{"rate":"common","effect":"Discoloration of body fluids (rifabutin)"},{"rate":"1-3","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL444633","moleculeType":"Small molecule","molecularWeight":"847.02"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clarithromycin is a macrolide antibiotic that binds to bacterial 50S ribosomal subunits to inhibit protein synthesis. Rifabutin is a rifamycin that inhibits bacterial RNA polymerase, blocking transcription. This combination is particularly effective against Mycobacterium avium complex (MAC) and other mycobacterial pathogens, with synergistic activity against resistant strains.","oneSentence":"Clarithromycin and rifabutin are macrolide and rifamycin antibiotics that inhibit bacterial protein synthesis and RNA-dependent RNA polymerase, respectively, used together to treat mycobacterial infections.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:37.312Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mycobacterium avium complex (MAC) infection prophylaxis and treatment in immunocompromised patients"},{"name":"Tuberculosis and atypical mycobacterial infections"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT04630145","phase":"PHASE2, PHASE3","title":"A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-01-08","conditions":"Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","enrollment":129},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT04616924","phase":"PHASE3","title":"RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease","status":"TERMINATED","sponsor":"RedHill Biopharma Limited","startDate":"2020-12-01","conditions":"Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases","enrollment":12},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT04553406","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease","status":"TERMINATED","sponsor":"Spero Therapeutics","startDate":"2020-12-03","conditions":"Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease","enrollment":2},{"nctId":"NCT03709355","phase":"PHASE1","title":"Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-11-14","conditions":"HIV-1-infection","enrollment":56},{"nctId":"NCT00001047","phase":"PHASE3","title":"Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":400},{"nctId":"NCT00001058","phase":"PHASE2","title":"A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":246},{"nctId":"NCT00001030","phase":"PHASE3","title":"The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":1100},{"nctId":"NCT00000826","phase":"PHASE1","title":"Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Bacterial Infections, Mycoses, HIV Infections","enrollment":48},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04652284","phase":"PHASE3","title":"Effectiveness of Rifabutin for Treatment of Helicobacter Pylori","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2021-05-01","conditions":"Helicobacter Infections, Resistance Bacterial, Gastritis H Pylori","enrollment":300},{"nctId":"NCT03009396","phase":"PHASE3","title":"Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2017-03-18","conditions":"Crohn Disease","enrollment":54},{"nctId":"NCT04107194","phase":"PHASE3","title":"Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.","status":"UNKNOWN","sponsor":"University of Bari","startDate":"2020-01-14","conditions":"Helicobacter Pylori Infection, Antibiotic Resistant Infection, Antibiotic Resistant Strain","enrollment":362},{"nctId":"NCT01951326","phase":"PHASE3","title":"Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2013-09","conditions":"Crohn's Disease","enrollment":331},{"nctId":"NCT00513552","phase":"PHASE4","title":"Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis","status":"WITHDRAWN","sponsor":"Medstar Health Research Institute","startDate":"2007-07","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT04090021","phase":"PHASE4","title":"Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.","status":"UNKNOWN","sponsor":"Konstantopoulio-Patission General Hospital of Nea Ionia","startDate":"2019-09-01","conditions":"Helicobacter Pylori Infection","enrollment":304},{"nctId":"NCT00598897","phase":"PHASE4","title":"Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1995-08","conditions":"Mycobacterium Avium Complex Lung Disease","enrollment":89},{"nctId":"NCT01717664","phase":"PHASE2","title":"Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2013-06","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":18},{"nctId":"NCT00001023","phase":"NA","title":"The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":91},{"nctId":"NCT00002101","phase":"PHASE3","title":"A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo","status":"COMPLETED","sponsor":"Pharmacia","startDate":"","conditions":"Mycobacterium Avium-Intracellulare Infection, HIV Infections","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Biaxin, mycobutin"],"phase":"marketed","status":"active","brandName":"clarithromycin, rifabutin","genericName":"clarithromycin, rifabutin","companyName":"The University of Texas Health Science Center at Tyler","companyId":"the-university-of-texas-health-science-center-at-tyler","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clarithromycin and rifabutin are macrolide and rifamycin antibiotics that inhibit bacterial protein synthesis and RNA-dependent RNA polymerase, respectively, used together to treat mycobacterial infections. Used for Mycobacterium avium complex (MAC) infection prophylaxis and treatment in immunocompromised patients, Tuberculosis and atypical mycobacterial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}